Corcept Therapeutics (FRA:HTD) Marketable Securities: €198.5 Mil (As of Mar. 2026)


FRA:HTD Corcept Therapeutics Inc FRA:HTD
82 GF Score
Price €80.28
GF Value €54.90
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Marketable Securities?

Corcept Therapeutics FRA:HTD +3.67% 82 Marketable Securities is €198.5 Mil as of Mar. 2026. GuruFocus rates FRA:HTD with a GF Score™ of 82/100 and a GF Value™ of €54.90 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Corcept Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was €198.5 Mil.

Corcept Therapeutics's annual Marketable Securities increased from Dec. 2023 (€213.4 Mil) to Dec. 2024 (€244.2 Mil) but then declined from Dec. 2024 (€244.2 Mil) to Dec. 2025 (€214.9 Mil).

Corcept Therapeutics  (FRA:HTD) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Corcept Therapeutics Marketable Securities Related Terms

Corcept Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Marketable Securities Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 129.14 344.88 213.36 244.16 214.92

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 215.47 207.63 252.66 214.92 198.47
FRA:HTD
82GF Score
Corcept Therapeutics Inc FRA:HTD
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €198.5 Mil mean?
Corcept Therapeutics (FRA:HTD) has a Marketable Securities of €198.5 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Marketable Securities too high?
Corcept Therapeutics' current Marketable Securities is €198.5 Mil. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Marketable Securities compare to PRAX and IBRX?
Corcept Therapeutics' Marketable Securities of €198.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Marketable Securities is €198.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €54.90, compared to a current price of €80.28 — trading 46.2% above its estimated fair value. The current Marketable Securities is €198.5 Mil. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Marketable Securities is €198.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €80.28 is trading 46.2% above its estimated GF Value™ of €54.90. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HTD:

  • Marketable Securities: €198.5 Mil
  • GF Value™: €54.90 vs. price of €80.28 (46.2% above fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Other Exchanges CORT:USA1CORT:Italy0I3Q:UK
Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score

Get the complete analysis for FRA:HTD

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€80.28
Price
€54.90
GF Value